Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emily Tonin da Costa
Observed name:
Emily Tonin Da Costa
Institutions:
Universidade Federal do Rio Grande do Sul,
Latin American Cooperative Oncology Group (LACOG)
Observed institutions:
Universidade Federal do Rio Grande do Sul,
Universidade Federal da Paraíba,
Hospital Moinhos de Vento,
Hospital de Clínicas de Porto Alegre,
Latin American Cooperative Oncology Group (LACOG)
ORCID:
0000-0003-0899-1454
Observed ORCID:
0000-0003-0899-1454
OpenAlex ID:
A5069579034
Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
·
Clinical Cancer Research
·
16
Gastric Cancer: Molecular Characterization, Therapeutic Innovations, and Perspectives
2024
·
Emily Tonin da Costa
, Sergio Jobim de Azevedo
, et al.
·
Brazilian Journal of Oncology
·
1
PDF
O impacto dos custos econômicos indiretos das pacientes com Câncer de colo uterino
2022
·
Emily Tonin da Costa
, Janaína Brollo
, et al.
·
Europub Journal of Health Research
·
1
PDF
Sequência de Pierre Robin: aplicação da técnica de distração osteogênica em pacientes como abordagem terapêutica
2016
·
Emily Tonin da Costa
, Carlos André Tarrio Gandara
, et al.
·
Rev. AMRIGS
·
1
Ultra-Hypofractionation in Breast Cancer: A Multicenter Retrospective Cohort Study in Brazil
2026
·
Gustavo Nader Marta
, Liêvin Matos Rebouças
, et al.
·
Clinical Breast Cancer
PDF
Sexuality in Women with Ostomies Due to Colorectal Cancer: A Qualitative Analysis
2026
·
Emily Tonin da Costa
, Juliana Lopes de Macedo
, et al.
·
Brazilian Journal of Oncology
Study Participants1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Table 2 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 2C from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 4B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Table 1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Methods1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Table 5 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Table 4 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 3A from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Data from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 3B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 4A from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 4C from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 2A from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Data1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Table 3 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 2B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Supplementary Figure 3C from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024
·
Pedro Isaacsson Velho
, Diogo Assed Bastos
, et al.
Show more works
View as search
Works count:
28
Citation count:
19
H-index:
1
I10-index:
1
Year
Topic
Type